

June 28, 2021

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Sub : Disclosure of Related Party Transactions for the half year ended 31st March 2021.
Ref : Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended 31st March 2021.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. R.

B Adi Reddy
Company Secretary



Encl: as above.

Aurobindo Pharma Limited

Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2021

(All amounts are in Indian Rupees in millions)

i) Names of related parties and description of relationship

a) Joint ventures

Novagen Pharma (Pty) Limited, South Africa (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)
Eugia Pharma Specialities Limited, India (Joint venture of a subsidiary, Curepro Parenterals Limited, India) upto 6 November, 2020
Tergene Biotech Private Limited, India
Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)
Purple Bellflower (Pty)Ltd, South Africa (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)
Luoxin Aurovitas Pharma (Chengdu) Co. Ltd. (Joint Venture of a subsidiary, Helix Healthcare B.V., The Netherlands)
Longxiang Pharma Taizhou Co. Ltd. (Joint Venture of a subsidiary, Helix Healthcare B.V., The Netherlands)
Novagen BBBEE Invest Co (Pty) Ltd (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)

b) Enterprises over which key management personnel or their relatives exercise significant influence

Pravesha Industries Private Limited, India
Sri Sai Packaging, India (Partnership firm)
Trident Chemphar Limited, India
Auropro Soft Systems Private Limited, India
Axis Clinicals Limited, India
Pranit Packaging Private Limited, India
SGD Pharma India Limited (formerly Cogent Glass Limited), India
Orem Access Bio Inc, India
Veritaz Healthcare Limited, India
Alex Merchant PTE. LTD, Singapore
Axis Clinicals LLC, USA
Alex Merchant DMCC, Dubai
Crest Cellulose Private Limited, India
East Pharma Technologies, India (Partnership firm)
Axis Clinicals Latina SA DE CV, Mexico
Gelcaps Industries, India
Aurobindo Pharma Foundation(Trust), India
Alcedo Pharmachem Private Limited, India
Ambipack Industries, India
Giyaan Pharma Private Limited, India
Sathguru Management Consultants Pvt.Ltd, India
Transaction Square LLP, India
Shreas Industries Limited, India
Aurobindo Realty & Infrastructure Private Limited, India
Aurobindo Pharma Foundation (SEC 8 Company), India

c) Key managerial personnel

Mr. K. Nityananda Reddy, Whole-time Director
Dr. M. Sivakumaran, Whole-time Director
Mr. M. Madan Mohan Reddy, Whole-time Director
Mr. P. Sarath Chandra Reddy, Whole-time Director
Mr. N. Govindarajan, Managing Director
Mr. Santhanam Subramanian, Chief Financial Officer
Mr. B. Adi Reddy, Company Secretary
Mr. K. Ragunathan, Non-executive Chairman and Independent Director
Mr. M. Sitarama Murty, Independent Director (up to 31 March 2021)
Dr. (Mrs.) Avnit Bimal Singh, Independent Director
Mr.P.Venkata Ramprasad Reddy, Non Executive promoter director
Mrs.Savitha Mahajan, Independent Director
Mr.Girish Paman Vanvari, Independent Director (w.e.f. 5 November 2020)

d) Relatives to key managerial personnel

Mr. Vishnu M Sriram (Son in law of Dr. M. Sivakumaran, Wholetime Director)



Aurobindo Pharma Limited**Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2021**

(All amounts are in Indian Rupees in millions)

ii) Transactions with related parties**a. Transactions with joint ventures**

	For the half year ended
Raldurgam Developers Limited	
Rent expenses including maintenance	59.5
Rent Deposit	100.6
Investment in optionally convertible debentures	259.5
Interest accrued	31.4
Novagen Pharma (Pty) Limited, South Africa	
Sale of products	104.8
Dividend received	0.1
Sale of services	17.3
Purple Bell Flower (Pty) Limited, South Africa	
Dividend received	2.5
Dividends Paid	5.2
Loans and Advances given	0.1
Eugla Pharma Specialities Ltd, India	
Sale of products	6.6
Purchases	862.8
Tergene Biotech Pvt. Ltd, India	
Investment in 10.5% Cumulative Redeemable Preference shares	22.0
Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	
Equity contribution	128.9
Novagen BBEE Invest Co (Pty) Ltd	
Options granted	0.3

b. Transactions with enterprises over which key management personnel or their relatives exercise significant influence

	For the half year ended
Pravesha Industries Private Limited, India	
Sale of products	0.1
Purchases	1,633.3
Sri Sai Packaging, India	
Sale of products	0.2
Purchases	118.7
Axis Clinicals Limited, India	
Sale of products	0.1
Purchase of services	1,461.9
Purchases	12.1
Reimbursement of expenses	0.5
Axis Clinicals LLC, USA	
Purchase of services	394.2
Trident Chemphar Limited, India	
Purchases	249.4
Purchase of services	70.9
Sale of products	0.1
Prant Packaging Private Limited, India	
Purchases	131.7
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Purchases	663.1



Aurobindo Pharma Limited

Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2021

(All amounts are in Indian Rupees in millions)

b. Transactions with enterprises over which key management personnel or their relatives exercise significant influence (continued)

	For the half year ended
Orem Access Bio Inc, India	
Purchases	127.8
Veritaz Healthcare Limited, India	
Sale of products	111.4
Rent received	0.2
Purchases	92.4
Crest Cellulose Private limited, India	
Purchases	161.7
East Pharma Techonologies, India	
Purchases	52.7
Gelcaps Industries, India	
Purchases	261.3
Sale of products	3.2
Aurobindo Foundation(Trust), India	
Contribution towards CSR activities	42.9
Corporate guarantee given	990.0
Aurobindo Pharma Foundation, India (Sec.8 Company)	
Contribution towards CSR activities	542.1
Equity contribution	0.1
Aicedo Pharmachem Private Limited, India	
Purchases	118.7
Ambipack Industries, India	
Purchases	69.4
Aurobindo Realty & Infrastructure Private Limited	
Purchase of capital goods	349.9
Shreas Industries Limited	
Purchases	0.9
Sathguru Management Consultants Pvt.Ltd.	
Purchase of services	1.2

c. Remuneration and sitting fees to key managerial personnel or their relatives

	For the half year ended
Salaries and other benefits*	132.4
Contributions to defined contribution plans	3.4
Director sitting fees	7.7
Commission	125.0

d. Transactions with key managerial personnel

	For the half year ended
Mr. K Nityananda Reddy	
Rent expense	1.4

Note:

*Salaries and other benefits does not include provision for gratuity and leave encashment, which is determined for the Company as a whole.

iii) Closing balances of related parties

a. Balances with Joint ventures at the year end

	As at 31 March 2021
Novagen Pharma (Pty) Limited, South Africa	
Balance receivable	100.0
Dividend receivable	337.1
Purple Bell Flower (Pty) Limited, South Africa	
Balance receivable	0.1
Dividend receivable	2.7
Raidurgam Developers Limited, India	
Balance receivable	24.0
Balance payable	22.9
Rent Deposit Receivable	100.6



Aurobindo Pharma Limited

Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2021

(All amounts are in Indian Rupees in millions)

b. Balances with enterprises over which key management personnel or their relatives exercise significant influence at the year end

	As at 31 March 2021
Pravesha Industries Private Limited, India	
Balance payable	835.3
Sri Sai Packaging, India	
Balance payable	46.8
Axis Clinicals Limited, India	
Balance payable	696.6
Trident Chemphar Limited, India	
Balance payable	12.4
Pranit Packaging Private Limited, India	
Balance receivable	0.3
Balance payable	48.4
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Balance payable	316.2
Veritaz Healthcare Limited, India	
Balance receivable	93.2
Balance payable	25.0
Orem Access Blo Inc, India	
Balance payable	30.5
Crest Cellulose Private Limited, India	
Balance payable	79.6
East Pharma Technologies, India	
Balance payable	22.3
Gelcaps Industries, India	
Balance receivable	0.3
Balance payable	118.6
Axis Clinicals LLC, USA	
Balance receivable	28.4
Balance payable	293.3
Amblpack Industries, India	
Balance payable	28.2
Glyaan Pharma Private Limited, India	
Balance receivable	27.3
Aurobindo Realty & Infrastructure Private Limited	
Balance receivable	73.3

c. Balances with key managerial personnel at the year end

	As at 31 March 2021
Mr.N Govindarajan	
Balance payable	125.0
Mr. K Nityananda Reddy	
Balance payable	0.2

